Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melanie Thompson

Showing results (11-20 of 60) with videos related to

Pageof 6
Sort By:
AIDS and Behavior|September 21, 2020
Core Elements of a National COVID-19 Strategy: Lessons Learned from the US National HIV/AIDS StrategyDavid R Holtgrave, Ronald O Valdiserri, Seth C Kalichman, et al.
Frontiers in Microbiology|May 1, 2014
Glutamine synthetase 2 is not essential for biosynthesis of compatible solutes in Halobacillus halophilusAnna Shiyan, Melanie Thompson, Saskia Köcher, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 27, 2007
Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapyCarl Grunfeld, Melanie Thompson, Stephen J Brown, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 21, 2004
Health-related quality of life with enfuvirtide (ENF; T-20) in combination with an optimized background regimenCalvin J Cohen, Nathan Clumeck, Jean-Michel Molina, et al.
Plos One|July 2, 2016
Can, Want and Try: Parents' Viewpoints Regarding the Participation of Their Child with an Acquired Brain InjuryMelanie Thompson, Catherine Elliott, Claire Willis, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 13, 2004
Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patientsDonald P Kotler, Norma Muurahainen, Carl Grunfeld, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 18, 2003
When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4+ lymphocyte counts <350 cells/microLJonathan E Kaplan, Debra L Hanson, David L Cohn, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 3, 2006
Effects of growth hormone on visceral adipose tissue and dyslipidemia in HIV, an erratumDonald P Kotler, Norma Muurahainen, Carl Grunfeld, et al.
AIDS (London, England)|December 5, 2015
A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virusMelanie Thompson, Michael Saag, Edwin DeJesus, et al.
AIDS (London, England)|October 13, 2020
Changes in weight and BMI with first-line doravirine-based therapyChloe Orkin, Richard Elion, Melanie Thompson, et al.
Pageof 6

Showing results (11-20 of 60) with videos related to

Sort By:
Pageof 6
AIDS and Behavior|September 21, 2020
Core Elements of a National COVID-19 Strategy: Lessons Learned from the US National HIV/AIDS StrategyDavid R Holtgrave, Ronald O Valdiserri, Seth C Kalichman, et al.
Frontiers in Microbiology|May 1, 2014
Glutamine synthetase 2 is not essential for biosynthesis of compatible solutes in Halobacillus halophilusAnna Shiyan, Melanie Thompson, Saskia Köcher, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 27, 2007
Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapyCarl Grunfeld, Melanie Thompson, Stephen J Brown, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 21, 2004
Health-related quality of life with enfuvirtide (ENF; T-20) in combination with an optimized background regimenCalvin J Cohen, Nathan Clumeck, Jean-Michel Molina, et al.
Plos One|July 2, 2016
Can, Want and Try: Parents' Viewpoints Regarding the Participation of Their Child with an Acquired Brain InjuryMelanie Thompson, Catherine Elliott, Claire Willis, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 13, 2004
Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patientsDonald P Kotler, Norma Muurahainen, Carl Grunfeld, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 18, 2003
When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4+ lymphocyte counts <350 cells/microLJonathan E Kaplan, Debra L Hanson, David L Cohn, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 3, 2006
Effects of growth hormone on visceral adipose tissue and dyslipidemia in HIV, an erratumDonald P Kotler, Norma Muurahainen, Carl Grunfeld, et al.
AIDS (London, England)|December 5, 2015
A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virusMelanie Thompson, Michael Saag, Edwin DeJesus, et al.
AIDS (London, England)|October 13, 2020
Changes in weight and BMI with first-line doravirine-based therapyChloe Orkin, Richard Elion, Melanie Thompson, et al.
Pageof 6